LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study

被引：10

作者：

Pautier, P. ^{[1
]}

Italiano, A. ^{[2
]}

Piperno-Neumann, S. ^{[3
]}

Chevreau, C. M. ^{[4
]}

Penel, N. ^{[5
]}

Cupissol, D. ^{[6
]}

Rouquette, P. Boudou ^{[7
]}

Bertucci, F. ^{[8
]}

Balleyguier, C. ^{[9
]}

Lebrun-Ly, V. ^{[10
]}

Blay, J-Y. ^{[11
]}

Kalbacher, E. ^{[12
]}

Delcambre, C. ^{[13
]}

Bompas, E. ^{[14
]}

Collard, O. ^{[15
]}

Isambert, N. ^{[16
]}

Guillemet, C. ^{[17
]}

Rios, M. ^{[18
]}

Sundqvist, M. ^{[19
]}

Duffaud, F. ^{[20
]}

机构：

[1] Inst Gustave Roussy, Med Dept, Villejuif, France

[2] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France

[3] Inst Curie, Med Dept, Paris, France

[4] Inst Univ Canc Toulouse Oncopole, Oncol Dept, Toulouse, Haute Garonne, France

[5] Ctr Oscar Lambret, Gen Oncol Dept, Lille, France

[6] Inst Canc Montpellier, Med Dept, Montpellier, France

[7] Hop Cochin, AP HP, Med Oncol Dept, Site Port Royal, Paris, France

[8] Inst Paoli Calmettes, Med Oncol Dept, Marseille, France

[9] Inst Gustave Roussy, Radiol Dept, Villejuif, France

[10] Ctr Hosp Univ, Med Oncol, Limoges, France

[11] Ctr Leon Berard, Med Dept, Lyon, France

[12] Hop Jean Minjoz, Med Dept, Besancon, France

[13] Ctr Francois Baclesse, Med Dept, Caen, France

[14] Inst Cancerol Ouest, Med Dept, Nantes, France

[15] Inst Cancerol Lucien Neuwirth, Med Dept, St Priest En Jarez, France

[16] CHU Poitiers, Med Oncol, Poitiers, France

[17] Ctr Henri Becquerel, Med Dept, Rouen, France

[18] Inst Cancerol Lorraine, Med, Vandoeuvre Les Nancy, France

[19] Gustave Roussy, Biostat & Epidemiol Dept, Canc Campus, Villejuif, France

[20] APHP Marseilles, Med Oncol, Marseilles, France

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.2139

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA59

引用

页码：S1335 / S1336

页数：2

共 50 条

[1] Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04) a randomised, multicentre, open-label phase 3 trial
Pautier, Patricia
Italiano, Antoine
Piperno-Neumann, Sophie
Chevreau, Christine
Penel, Nicolas
Firmin, Nelly
Boudou-Rouquette, Pascaline
Bertucci, Francois
Balleyguier, Corinne
Lebrun-Ly, Valerie
Ray-Coquard, Isabelle
Kalbacher, Elsa
Bardet, Aurelie
Bompas, Emmanuelle
Collard, Olivier
Isambert, Nicolas
Guillemet, Cecile
Rios, Maria
Archambaud, Baptiste
Duffaud, Florence
[J]. LANCET ONCOLOGY, 2022, 23 (08): : 1044 - 1054
[2] A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as firstline therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study
Pautier, P.
Italiano, A.
Piperno-Neumann, S.
Chevreau, C. M.
Penel, N.
Firmin, N.
Rouquette, P. Boudou
Bertucci, F.
Le Brun-Ly, V.
Ray-Coquard, I. L.
Kalbacher, E.
Bompas, E.
Collard, O.
Isambert, N.
Guillemet, C.
Rios, M.
Le Cesne, A.
Archambaud, B.
Duffaud, F.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1030 - S1030
[3] Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study
Martin-Broto, Javier
Lopez Pousa, Antonio
de las Penas, Ramon
Garcia del Muro, Xavier
Gutierrez, Antonio
Martinez-Trufero, Javier
Cruz, Josefina
Alvarez, Rosa
Cubedo, Ricardo
Redondo, Andres
Maurel, Joan
Carrasco, Juan A.
Lopez-Martin, Jose A.
Sala, Angeles
Andres Meana, Jose
Ramos, Rafael
Martinez-Serra, Jordi
Lopez-Guerrero, Jose A.
Sevilla, Isabel
Balana, Carmen
Vaz, Angeles
De Juan, Ana
Alemany, Regina
Poveda, Andres
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (19) : 2294 - +
[4] Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma
Cote, Gregory Michael
Chawla, Sant P.
Demetri, George
Kasper, Bernd
Jones, Robin Lewis
Broto, Javier Martin
Wooley, Joseph
Weiss, Mia C.
Tafuto, Salvatore
Badalamenti, Giuseppe
Carrasco-Garcia, Irene
Peinado, Paloma
Blay, Jean-Yves
Boggio, Gaston
Fernandez, Cristian Marcelo
Nieto, Antonio
Kahatt, Carmen Maria
Zeaiter, Ali Hassan
Le Cesne, Axel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS).
Blay, Jean-Yves
Leahy, Michael Gordon
Binh Bui Nguyen
Patel, Shreyaskumar
Santoro, Armando
Hohenberger, Peter
Demetri, George D.
Lardelli, Pilar
Perez, Iratxe
Chawla, Sant P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[6] A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial
Bui-Nguyen, B.
Butrynski, J. E.
Penel, N.
Blay, J. Y.
Isambert, N.
Milhem, M.
Kerst, J. M.
Reyners, A. K. L.
Litiere, S.
Marreaud, S.
Collin, F.
van der Graaf, W. T. A.
[J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) : 1312 - 1320
[7] LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS.
Pautier, Patricia
Floquet, Anne
Cupissol, Didier
Lacas, Benjamin
Bompas, Emmanuelle
Chevreau, Christine
Selle, Frederic
Weber, Beatrice E.
Guillemet, Cecile
Penel, Nicolas
Duffaud, Florence
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[8] Randomized phase II trial of doxorubicin vs. trabectedin plus doxorubicin in first line treatment of patients with advanced non-resectable or metastatic soft tissue sarcomas: a Spanish Group for Sarcoma Research (GEIS) study
Martin-Broto, J.
Lopez-Pousa, A.
Garcia del Muro, X.
De Las Penas, R.
Martinez-Trufero, J.
Cruz, J.
Alvarez, R.
Cubedo, R.
Redondo, A.
Poveda, A.
[J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S875 - S875
[9] Results of the randomized phase III trial of trabectedin (F) versus doxorubicin-based chemotherapy (DXCT) as First-line therapy in patients (pts) with translocation-related sarcoma (TRS).
Hendifar, Andrew Eugene
Chawla, Sant P.
Leahy, Michael Gordon
Italiano, Antoine
Patel, Shreyaskumar
Santoro, Armando
Staddon, Arthur P.
Penel, Nicolas
Piperno-Neumann, Sophie
Demetri, George D.
Hayward, Larry
White, Jeff
Gouw, Launce G.
De Miguel, Bernardo
Lardelli, Pilar
Soto, Arturo
Nieto, Antonio
Blay, Jean-Yves
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[10] A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study.
Pautier, Patricia
Floquet, Anne
Chevreau, Christine
Penel, Nicolas
Guillemet, Cecile
Delcambre, Corinne
Cupissol, Didier
Selle, Frederic
Isambert, Nicolas
Piperno-Neumann, Sophie
Saada-Bouzid, Esma
Bertucci, Francois
Bompas, Emmanuelle
Boudou-Rouquette, Pascaline
Collard, Olivier
Ly, Valerie Le Brun
Toulmonde, Maud
Le Cesne, Axel
Lacas, Benjamin
Duffaud, Florence
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →